Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas,Growth Hormone and IGF Research

当前位置： X-MOL 学术 › Growth Horm. IGF Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas
Growth Hormone and IGF Research ( IF 1.4 ) Pub Date : 2020-09-24 , DOI: 10.1016/j.ghir.2020.101356
Hande Mefkure Ozkaya ₁ , Serdar Sahin ₁ , Ozge Polat Korkmaz ₁ , Emre Durcan ₁ , Humeyra Rekali Sahin ₂ , Emir Celik ₃ , Burc Cagri Poyraz ₄ , Pinar Kadioglu ₁

Affiliation

Objective

To evaluate the prevalence of impulse control disorders (ICD) and psychiatric symptoms in patients with acromegaly receiving dopamine agonists (DA) in comparison with those with prolactinoma, nonfunctioning pituitary adenomas (NFA), and healthy controls (HC).

Design

Forty patients with acromegaly, 40 with prolactinoma, 38 with NFA, and 32 HCs were included. All patients and controls were evaluated using the revised version of the Minnesota Impulsive Disorders Interview (MIDI-R), Symptom Check List (SCL-90-R) questionnaire, Barratt Impulsiveness Scale (BIS-11), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI).

Results

We detected ICD associated with DAs in two patients with acromegaly (5%) and three patients (7.5%) with prolactinoma. All patients' symptoms resolved after discontinuation of the drug. While the mean DA dose was higher in patients with acromegaly than prolactinomas (p < 0.05), no difference was detected in terms of ICD prevalence between two groups (p > 0.05). SCL-90 depression and interpersonal sensitivity subscale positivity was higher in patients with NFA than HCs. Patients with prolactinoma had higher obsession and interpersonal sensitivity positivity and those with NFA had higher somatization, interpersonal sensitivity, and depression positivity as compared to patients with acromegaly (p < 0.05 for all).

Conclusions

Although DA dose was significantly higher in patients with acromegaly, there was no significant difference in the prevalence of DA-related ICD. The higher prevalence of positive screening in SCL-90 in patients with NFA in comparison to HCs supports the hypothesis that the presence of a pituitary adenoma per se might cause significant psychiatric symptoms.

中文翻译：

与泌乳素瘤患者相比，肢端肥大症患者患多巴胺激动剂诱发的冲动控制障碍的风险可能并不高

客观的

评估接受多巴胺激动剂 (DA) 的肢端肥大症患者与催乳素瘤、无功能垂体腺瘤 (NFA) 和健康对照 (HC) 患者的冲动控制障碍 (ICD) 和精神症状的患病率。

设计

包括 40 名肢端肥大症患者、40 名催乳素瘤患者、38 名 NFA 患者和 32 名 HC。使用修订版的明尼苏达冲动性障碍访谈 (MIDI-R)、症状检查表 (SCL-90-R) 问卷、巴拉特冲动量表 (BIS-11)、贝克抑郁量表 (BDI)、和贝克焦虑量表（BAI）。

结果

我们在两名肢端肥大症患者 (5%) 和三名催乳素瘤患者 (7.5%) 中检测到与 DA 相关的 ICD。所有患者在停药后症状均消失。虽然肢端肥大症患者的平均 DA 剂量高于催乳素瘤患者 ( p < 0.05)，但两组之间的 ICD 患病率没有检测到差异 ( p > 0.05)。NFA 患者的 SCL-90 抑郁和人际关系敏感性分量表阳性率高于 HC。与肢端肥大症患者相比，催乳素瘤患者具有更高的强迫观念和人际关系敏感性阳性，而 NFA 患者具有更高的躯体化、人际关系敏感性和抑郁阳性（p < 0.05）。